Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 4Phase 1 3Phase 1/2 1

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2Genitourinary 2Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 522Leukemia, Myeloid, Acute 499Neoplasms 380Carcinoma, Non-Small-Cell Lung 380Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 318Multiple Myeloma 312Glioblastoma 311Melanoma 309Prostatic Neoplasms 293Leukemia 288Neoplasm Metastasis 284Brain Neoplasms 275Lymphoma 271Lung Neoplasms 269Recurrence 266Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Myelodysplastic Syndromes 208Glioma 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 161Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Etoposide 1Disulfides 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Endocrine Gland Neoplasms × Clear all
NCT05335811 2026-05-20

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

M.D. Anderson Cancer Center

Phase 1 Recruiting
55 enrolled

Endocrine Gland Neoplasms

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03420963 2026-03-20

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Terminated
12 enrolled
DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡